logo

Can-Fite Biopharma Ltd. (CANF)



Trade CANF now with
  Date
  Headline
8/27/2020 7:05:35 AM Can-Fite 5-month Loss Per Share $0.04 Vs Loss $0.08 Last Year
8/25/2020 8:14:14 AM Can-Fite Receives Notification Of Patent Grant From European Patent Office For Namodenoson In The Treatment Of NASH
7/27/2020 7:13:40 AM Can-Fite Submits IND To FDA For COVID-19 Phase II Study Of Piclidenoson
7/15/2020 7:07:49 AM Can-Fite BioPharma Amends Phase II COVID-19 Study Protocol Based On Inputs From FDA
6/10/2020 8:07:39 AM Can-Fite Plans $8.0 Mln Registered Direct Offering
6/9/2020 7:07:07 AM Can-Fite BioPharma To Advance Piclidenoson Into Phase II COVID-19 Trial In The U.S.
6/1/2020 7:14:09 AM Can-Fite Q1 Loss Per Share $0.03 Vs Loss $0.04 Last Year
5/21/2020 7:13:57 AM Can-Fite Receives Notice Of Allowance For Namodenoson Patent In The NASH & NAFLD From U.S. Patent And Trademark Office
5/15/2020 7:08:07 AM CANF Files Pre-IND With FDA For Piclidenoson In Treatment Of COVID-19 Infected Patients With Moderate-to-Severe Symptoms
4/13/2020 6:35:32 AM Can Fite BioPharma Gets Approval For COVID-19 Clinical Trial In Israel, Patient Enrollment, Dosing To Begin Immediately
3/30/2020 7:07:09 AM Can-Fite Implements Interim Analysis For Its Phase III Psoriasis Trial To Evaluate Piclidenoson
3/27/2020 7:09:33 AM Can-Fite FY Net Loss $9.5 Mln Vs Loss Of $6.6 Mln Last Year
3/23/2020 7:53:59 AM Can-Fite Submits Piclidenoson To Rabin Medical Center For Compassionate Use Treatment For Coronavirus Patients In Israel
3/16/2020 7:13:57 AM Can-Fite BioPharma Enrolls 7 Patients For Compassionate Use Program For Namodenoson For Hepatocellular Cancer
3/13/2020 7:05:29 AM Can-Fite Enters Collaborative Research Agreement With Lewis Katz School Of Medicine At Temple University
3/11/2020 7:38:28 AM Can-Fite Announces New Pre-clinical Studies Demonstrate Inhibition Of Fat Cell Expansion By Cannabis Derived CBD